Literature DB >> 16769789

Rituximab in the treatment of antisynthetase syndrome.

L Brulhart, J-M Waldburger, C Gabay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16769789      PMCID： PMC1798219          DOI： 10.1136/ard.2005.045898

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

Review 1.  Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes.

Authors:  C Marguerie; C C Bunn; H L Beynon; R M Bernstein; J M Hughes; A K So; M J Walport
Journal:  Q J Med       Date:  1990-10

2.  Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment.

Authors:  Armin Schnabel; Michael Reuter; Jürgen Biederer; Christiane Richter; Wolfgang L Gross
Journal:  Semin Arthritis Rheum       Date:  2003-04       Impact factor: 5.532

3.  Rituximab in the treatment of dermatomyositis: an open-label pilot study.

Authors:  Todd D Levine
Journal:  Arthritis Rheum       Date:  2005-02

4.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

5.  Pulmonary involvement in polymyositis and in dermatomyositis.

Authors:  I Marie; P Y Hatron; E Hachulla; B Wallaert; U Michon-Pasturel; B Devulder
Journal:  J Rheumatol       Date:  1998-07       Impact factor: 4.666

6.  Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Authors:  Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael R Ehrenstein; Martin Salden; Mark Bodman-Smith; Anthony D B Webster
Journal:  Arthritis Rheum       Date:  2003-08
  6 in total
  16 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

Review 2.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  [Rituximab for the treatment of poly- and dermatomyositis : Results from the GRAID-2 registry].

Authors:  C Fiehn; L Unger; H Schulze-Koops; F Proft; J C Henes; A Jacobi; T Dörner
Journal:  Z Rheumatol       Date:  2018-02       Impact factor: 1.372

Review 5.  Biologic therapy in the idiopathic inflammatory myopathies.

Authors:  Thomas Khoo; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-11-04       Impact factor: 2.631

Review 6.  Antisynthetase syndrome.

Authors:  Elena Katzap; Maria-Louise Barilla-LaBarca; Galina Marder
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 7.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

8.  Rituximab in life threatening antisynthetase syndrome.

Authors:  E Vandenbroucke; J C Grutters; J Altenburg; W G Boersma; E J ter Borg; J M M van den Bosch
Journal:  Rheumatol Int       Date:  2009-02-01       Impact factor: 2.631

Review 9.  Idiopathic inflammatory myopathies: current and future therapeutic options.

Authors:  Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

10.  Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide.

Authors:  Marisa Fernandes das Neves; Joana Caetano; Susana Oliveira; José Delgado Alves
Journal:  BMJ Case Rep       Date:  2015-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.